vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and FENNEC PHARMACEUTICALS INC. (FENC). Click either name above to swap in a different company.
FENNEC PHARMACEUTICALS INC. is the larger business by last-quarter revenue ($13.8M vs $9.4M, roughly 1.5× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -34.7%, a 1968.7% gap on every dollar of revenue. On growth, FENNEC PHARMACEUTICALS INC. posted the faster year-over-year revenue change (73.8% vs 10.1%). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -26.3%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
Fennec Pharmaceuticals Inc. is a biopharmaceutical firm focused on developing and commercializing therapies to reduce treatment-related side effects in pediatric cancer patients. Its lead product targets chemotherapy-induced ototoxicity, with core North American markets serving oncology providers and vulnerable pediatric patient groups.
BYFC vs FENC — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $13.8M |
| Net Profit | $1.0M | $-4.8M |
| Gross Margin | — | — |
| Operating Margin | — | -18.5% |
| Net Margin | 1934.0% | -34.7% |
| Revenue YoY | 10.1% | 73.8% |
| Net Profit YoY | -21.8% | -141.1% |
| EPS (diluted) | $0.02 | $-0.17 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | $13.8M | ||
| Q3 25 | $9.0M | $12.5M | ||
| Q2 25 | $8.1M | $9.7M | ||
| Q1 25 | $8.3M | $8.8M | ||
| Q4 24 | $8.6M | $7.9M | ||
| Q3 24 | $8.7M | $7.0M | ||
| Q2 24 | $8.2M | $7.3M | ||
| Q1 24 | $7.8M | $25.4M |
| Q4 25 | $1.0M | $-4.8M | ||
| Q3 25 | $-23.9M | $-638.0K | ||
| Q2 25 | $752.0K | $-3.2M | ||
| Q1 25 | $-2.7M | $-1.2M | ||
| Q4 24 | $1.3M | $-2.0M | ||
| Q3 24 | $516.0K | $-5.7M | ||
| Q2 24 | $256.0K | $-5.6M | ||
| Q1 24 | $-154.0K | $12.8M |
| Q4 25 | — | -18.5% | ||
| Q3 25 | -256.2% | -1.5% | ||
| Q2 25 | 12.8% | -28.3% | ||
| Q1 25 | -45.3% | -9.2% | ||
| Q4 24 | 21.7% | -11.8% | ||
| Q3 24 | 8.5% | -74.6% | ||
| Q2 24 | 4.8% | -69.4% | ||
| Q1 24 | -2.9% | 54.2% |
| Q4 25 | 1934.0% | -34.7% | ||
| Q3 25 | -264.2% | -5.1% | ||
| Q2 25 | 9.3% | -32.7% | ||
| Q1 25 | -32.3% | -13.3% | ||
| Q4 24 | 15.3% | -25.0% | ||
| Q3 24 | 5.9% | -82.2% | ||
| Q2 24 | 3.1% | -76.5% | ||
| Q1 24 | -2.0% | 50.6% |
| Q4 25 | $0.02 | $-0.17 | ||
| Q3 25 | $-2.86 | $-0.02 | ||
| Q2 25 | $0.00 | $-0.11 | ||
| Q1 25 | $-0.39 | $-0.04 | ||
| Q4 24 | $0.07 | $-0.02 | ||
| Q3 24 | $-0.03 | $-0.21 | ||
| Q2 24 | $0.02 | $-0.20 | ||
| Q1 24 | $-0.02 | $0.41 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $36.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $35.5M |
| Total Assets | $1.3B | $70.6M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | $36.8M | ||
| Q3 25 | $19.7M | $21.9M | ||
| Q2 25 | $29.5M | $18.7M | ||
| Q1 25 | $15.8M | $22.7M | ||
| Q4 24 | $61.4M | $26.6M | ||
| Q3 24 | $97.1M | $40.3M | ||
| Q2 24 | $89.8M | $43.1M | ||
| Q1 24 | $67.1M | $51.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | $19.4M | ||
| Q2 25 | — | $19.4M | ||
| Q1 25 | — | $19.4M | ||
| Q4 24 | — | $19.3M | ||
| Q3 24 | — | $32.1M | ||
| Q2 24 | — | $31.8M | ||
| Q1 24 | — | $31.3M |
| Q4 25 | $262.8M | $35.5M | ||
| Q3 25 | $261.7M | $-4.5M | ||
| Q2 25 | $284.7M | $-7.5M | ||
| Q1 25 | $283.6M | $-5.9M | ||
| Q4 24 | $285.0M | $-5.9M | ||
| Q3 24 | $286.2M | $-5.2M | ||
| Q2 24 | $282.1M | $-1.4M | ||
| Q1 24 | $281.1M | $3.0M |
| Q4 25 | $1.3B | $70.6M | ||
| Q3 25 | $1.3B | $49.3M | ||
| Q2 25 | $1.2B | $44.9M | ||
| Q1 25 | $1.3B | $46.4M | ||
| Q4 24 | $1.3B | $44.9M | ||
| Q3 24 | $1.4B | $58.9M | ||
| Q2 24 | $1.4B | $63.2M | ||
| Q1 24 | $1.4B | $69.2M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 10.40× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-6.0M |
| Free Cash FlowOCF − Capex | $-13.0K | — |
| FCF MarginFCF / Revenue | -0.1% | — |
| Capex IntensityCapex / Revenue | 2.6% | — |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | $-6.0M | ||
| Q3 25 | $3.8M | $1.5M | ||
| Q2 25 | $3.0M | $-3.7M | ||
| Q1 25 | $-4.3M | $-4.3M | ||
| Q4 24 | $1.4M | $-1.5M | ||
| Q3 24 | $6.1M | $-2.2M | ||
| Q2 24 | $9.8M | $-8.4M | ||
| Q1 24 | $-11.7M | $39.0M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | — | ||
| Q1 25 | $-4.4M | — | ||
| Q4 24 | $1.3M | — | ||
| Q3 24 | $6.1M | — | ||
| Q2 24 | $9.7M | — | ||
| Q1 24 | $-11.7M | — |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | — | ||
| Q1 25 | -52.4% | — | ||
| Q4 24 | 14.7% | — | ||
| Q3 24 | 69.6% | — | ||
| Q2 24 | 118.9% | — | ||
| Q1 24 | -149.7% | — |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.2% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 0.3% | — | ||
| Q2 24 | 0.5% | — | ||
| Q1 24 | 0.7% | — |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 1.06× | — | ||
| Q3 24 | 11.85× | — | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | 3.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
